Form 4: TScan CMO Acquires 420,000 Stock Options

TScan Therapeutics' Chief Medical Officer, Louis Chrystal, acquired 420,000 stock options with an exercise price of $1.12, vesting over four years.

Summary

• Louis Chrystal, Chief Medical Officer of TScan Therapeutics, Inc. (TCRX), acquired 420,000 stock options.
• The transaction date for the acquisition of these derivative securities was January 20, 2026.
• Each stock option has an exercise price of $1.12.
• The options grant the right to buy 420,000 shares of Voting Common Stock.
• The options will vest with respect to 25% of the shares on January 20, 2027 (the one-year anniversary of the grant date).
• The remaining balance of the options will vest in equal monthly installments over the subsequent 36 months.
• Vesting is contingent upon Louis Chrystal's continued service to the Issuer on each vesting date.
• The expiration date for these stock options is January 20, 2036.

Sentiment

Score: 7

Explanation: The acquisition of a significant number of stock options by a key executive suggests confidence in the company's future performance, aligning management's interests with shareholders. This is generally viewed as a positive signal.

Positives

• The acquisition of a significant number of stock options by a key executive, the Chief Medical Officer, signals confidence in the company's future prospects and aligns management's interests with those of shareholders.
• The long-term vesting schedule (four years) indicates a commitment from the executive to the company's sustained performance.

Future Outlook

The vesting schedule for the stock options extends over the next four years, indicating a long-term incentive structure for the Chief Medical Officer, contingent on continued service to the company.

Industry Context

The grant of stock options to a Chief Medical Officer is a standard practice in the biotechnology and pharmaceutical industries, serving as a key component of executive compensation to attract, retain, and incentivize top talent, particularly in companies focused on long-term drug development and clinical milestones.

Comparison to Industry Standards

• This type of equity compensation, involving stock options with a multi-year vesting schedule, is a common practice across the biotech and pharmaceutical sectors, comparable to compensation structures seen at companies like Moderna, BioNTech, or Regeneron for their executive teams.
• The specific number of options and exercise price would typically be benchmarked against peer companies of similar market capitalization and development stage, though the filing does not provide such comparative data.

Stakeholder Impact

• Shareholders: The grant aligns the Chief Medical Officer's financial interests with shareholder value creation, as the options gain value if the stock price increases.
• Employees: This type of executive compensation can set a precedent or standard for other employee incentive programs, potentially boosting morale and retention.

Next Steps

• The options will begin vesting on January 20, 2027, with subsequent monthly vesting installments over the following 36 months.
• The Chief Medical Officer may choose to exercise these options at any point after they vest and before their expiration date of January 20, 2036.

Key Dates

Recommendation

The grant of a substantial stock option package to the Chief Medical Officer is a positive signal, indicating management's long-term commitment and alignment with shareholder interests. However, this single event alone is not sufficient to change a broader investment thesis, warranting a 'hold' recommendation while monitoring future developments and financial performance.

Keywords

TScan Therapeutics, TCRX, Stock Option, Insider Transaction, Equity Compensation, Louis Chrystal, Chief Medical Officer, Form 4